CTLA4 and cancer: Compared with alternative ICIs,anti-PD-L1 monoclonal antibodies, including anti-CTLA-4 monoclonal antibodies, have shown prolonged beneficial effects in a diverse array of human cancer patients and exhibit reduced toxicity [15].